View in EDS HTML Full Text PDF Full Text

Budget impact of introducing an omalizumab biosimilar in 23 European countries.

Saved in:
Bibliographic Details
Title: Budget impact of introducing an omalizumab biosimilar in 23 European countries.
Authors: Jang M; Celltrion, Inc, Incheon, Republic of Korea., Lee J; Celltrion, Inc, Incheon, Republic of Korea., Yi S; Celltrion, Inc, Incheon, Republic of Korea., Kwon TS; Celltrion, Inc, Incheon, Republic of Korea.
Source: Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 1639-1650. Date of Electronic Publication: 2025 Sep 18.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40955168
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Budget impact of introducing an omalizumab biosimilar in 23 European countries.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jang+M%22">Jang M</searchLink>; Celltrion, Inc, Incheon, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+J%22">Lee J</searchLink>; Celltrion, Inc, Incheon, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Yi+S%22">Yi S</searchLink>; Celltrion, Inc, Incheon, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kwon+TS%22">Kwon TS</searchLink>; Celltrion, Inc, Incheon, Republic of Korea.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229892255%22">Journal of medical economics</searchLink> [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 1639-1650. <i>Date of Electronic Publication: </i>2025 Sep 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9892255 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1941-837X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213696998%22">13696998 </searchLink><i>NLM ISO Abbreviation: </i>J Med Econ <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40955168
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/13696998.2025.2558450
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1639
    Titles:
      – TitleFull: Budget impact of introducing an omalizumab biosimilar in 23 European countries.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jang M
      – PersonEntity:
          Name:
            NameFull: Lee J
      – PersonEntity:
          Name:
            NameFull: Yi S
      – PersonEntity:
          Name:
            NameFull: Kwon TS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1941-837X
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of medical economics
              Type: main
ResultId 1